Accéder au contenu
Merck
  • Alterations in Brain Inflammation, Synaptic Proteins, and Adult Hippocampal Neurogenesis during Epileptogenesis in Mice Lacking Synapsin2.

Alterations in Brain Inflammation, Synaptic Proteins, and Adult Hippocampal Neurogenesis during Epileptogenesis in Mice Lacking Synapsin2.

PloS one (2015-07-16)
Deepti Chugh, Idrish Ali, Anahita Bakochi, Elma Bahonjic, Lars Etholm, Christine T Ekdahl
RÉSUMÉ

Synapsins are pre-synaptic vesicle-associated proteins linked to the pathogenesis of epilepsy through genetic association studies in humans. Deletion of synapsins causes an excitatory/inhibitory imbalance, exemplified by the epileptic phenotype of synapsin knockout mice. These mice develop handling-induced tonic-clonic seizures starting at the age of about 3 months. Hence, they provide an opportunity to study epileptogenic alterations in a temporally controlled manner. Here, we evaluated brain inflammation, synaptic protein expression, and adult hippocampal neurogenesis in the epileptogenic (1 and 2 months of age) and tonic-clonic (3.5-4 months) phase of synapsin 2 knockout mice using immunohistochemical and biochemical assays. In the epileptogenic phase, region-specific microglial activation was evident, accompanied by an increase in the chemokine receptor CX3CR1, interleukin-6, and tumor necrosis factor-α, and a decrease in chemokine keratinocyte chemoattractant/ growth-related oncogene. Both post-synaptic density-95 and gephyrin, scaffolding proteins at excitatory and inhibitory synapses, respectively, showed a significant up-regulation primarily in the cortex. Furthermore, we observed an increase in the inhibitory adhesion molecules neuroligin-2 and neurofascin and potassium chloride co-transporter KCC2. Decreased expression of γ-aminobutyric acid receptor-δ subunit and cholecystokinin was also evident. Surprisingly, hippocampal neurogenesis was reduced in the epileptogenic phase. Taken together, we report molecular alterations in brain inflammation and excitatory/inhibitory balance that could serve as potential targets for therapeutics and diagnostic biomarkers. In addition, the regional differences in brain inflammation and synaptic protein expression indicate an epileptogenic zone from where the generalized seizures in synapsin 2 knockout mice may be initiated or spread.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Glycérol, for molecular biology, ≥99.0%
Sigma-Aldrich
Sodium Dodecyl Sulfate, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)
Sigma-Aldrich
Sodium Dodecyl Sulfate, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Sodium Dodecyl Sulfate solution, BioUltra, for molecular biology, 10% in H2O
Sigma-Aldrich
Glycérol, ≥99.5%
Sigma-Aldrich
Sodium Dodecyl Sulfate, ACS reagent, ≥99.0%
Sigma-Aldrich
Sodium Dodecyl Sulfate, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Glycérol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycérol solution, 83.5-89.5% (T)
Sigma-Aldrich
Sodium Dodecyl Sulfate solution, BioUltra, for molecular biology, 20% in H2O
Sigma-Aldrich
Sodium Dodecyl Sulfate, BioUltra, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Glycérol, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
Anticorps monoclonal anti-protéine acide fibrillaire gliale (GFAP) antibody produced in mouse, clone G-A-5, ascites fluid
Sigma-Aldrich
Glycérol, FCC, FG
Sigma-Aldrich
Monoclonal Anti-Parvalbumin antibody produced in mouse, clone PARV-19, ascites fluid
Sigma-Aldrich
Glycérol, BioXtra, ≥99% (GC)
Sigma-Aldrich
Dabco® 33-LV